摘要
目的对比观察美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的疗效及安全性。方法研究对象为2011年1月至2014年8月进行治疗的溃疡性结肠炎患者88例,随机分为治疗组、对照组。基础治疗基础上治疗组饭前1 h口服美沙拉嗪片,0.5克/次,3次/天。对照组口服柳氮磺胺吡啶片,起始剂量0.5~1克/次,3~4次/天,总剂量<3 g/d。治疗一段时间若无明显不良反应,则4~6 g/d,症状缓解后可逐渐减量至1.5~2 g/d维持治疗。两组均治疗8周。结果两组治疗后结肠黏膜组织学评分与同组内治疗前比较差异有统计学意义(P<0.05),两组间比较差异无统计学意义(P>0.05)。治疗组总有效率为95.45%,对照组总有效率为75.00%,两组比较差异有统计学意义(P<0.05)。治疗组出现恶心1例,不良反应发生率为2.27%;对照组出现恶心4例,皮疹4例,不良反应发生率为18.18%。两组比较差异有统计学意义(P<0.05)。结论美沙拉嗪治疗溃疡性结肠炎比柳氮磺吡啶疗效好,且安全性更高。
Objective To compare and observe the curative effect and safety of beautifulsalad diazoxide and sulfasalazine in treatment of ulcerative colitis. Methods The study object for the 2011 January-2014 year in August to 88 in patients with ulcerative colitis treated patients, randomly divided into treatment group, control group. Foundation treatment on the basis of the treatment group before lh oral mesalazinetablets, 0.5 g/times, 3 times/d. The control group oral sulfasalazine, initial dose of 0.5-1 g/, 3- 4 times/d, a total dose 〈3 g/d. Treatment for a period of time withoutobvious adverse reactions, 4-6 g/d, alleviate symptoms can be gradually reduced tol.5-2 g/d maintenance therapy. The two groups were treated for 8 weeks. Results Of the two groups after treatment of colonic mucosal histology scorecompared with the treatment in the same group before the difference was statistically significant （P〈0.05）. The total effective rate and of the incidence rate of adverse reaction of treatment group were 95.45% and 2.27%, and of the control group were 75.00% and 18.18%（P〈0.05）. Conclusion Mesalazine on ulcerative colitiscurative effect of sulfasalazine, and hi^her safety.
出处
《中国医药指南》
2015年第27期24-25,共2页
Guide of China Medicine
